Eliav Barr

20.1k total citations · 6 hit papers
75 papers, 10.4k citations indexed

About

Eliav Barr is a scholar working on Epidemiology, Hepatology and Surgery. According to data from OpenAlex, Eliav Barr has authored 75 papers receiving a total of 10.4k indexed citations (citations by other indexed papers that have themselves been cited), including 47 papers in Epidemiology, 24 papers in Hepatology and 17 papers in Surgery. Recurrent topics in Eliav Barr's work include Hepatitis B Virus Studies (35 papers), Cervical Cancer and HPV Research (33 papers) and Hepatitis C virus research (24 papers). Eliav Barr is often cited by papers focused on Hepatitis B Virus Studies (35 papers), Cervical Cancer and HPV Research (33 papers) and Hepatitis C virus research (24 papers). Eliav Barr collaborates with scholars based in United States, France and Canada. Eliav Barr's co-authors include Cosette M. Wheeler, Laura A. Koutsky, Kathrin U. Jansen, Kevin A. Ault, Darron R. Brown, Frances B. Alvarez, Jeffrey M. Leiden, Janine T. Bryan, Heather L. Sings and Mark T. Esser and has published in prestigious journals such as Science, New England Journal of Medicine and The Lancet.

In The Last Decade

Eliav Barr

75 papers receiving 9.9k citations

Hit Papers

Quadrivalent Vaccine against Human Papillomavirus to Prev... 2002 2026 2010 2018 2007 2002 2011 2006 2015 400 800 1.2k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Quadrivalent Vaccine against Human Papillomavirus to Prevent Anogenital Diseases
    2007 1.4k citations Cosette M. Wheeler, Janine T. Bryan et al. New England Journal of Medicine profile →
  2. A Controlled Trial of a Human Papillomavirus Type 16 Vaccine
    2002 1.2k citations Laura A. Koutsky, Kevin A. Ault et al. New England Journal of Medicine profile →
  3. Efficacy of Quadrivalent HPV Vaccine against HPV Infection and Disease in Males
    2011 821 citations Anna R. Giuliano, Joel M. Palefsky et al. New England Journal of Medicine profile →
  4. ADVISORY COMMITTEE ON IMMUNIZATION PRACTICES
    2006 648 citations Eliav Barr et al. profile →
  5. Grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and stage 4–5 chronic kidney disease (the C-SURFER study): a combination phase 3 study
    2015 477 citations David Roth, David R. Nelson et al. The Lancet profile →
  6. Grazoprevir–Elbasvir Combination Therapy for Treatment-Naive Cirrhotic and Noncirrhotic Patients With Chronic Hepatitis C Virus Genotype 1, 4, or 6 Infection
    2015 386 citations Reem Ghalib, Shuyan Wan et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Eliav Barr United States 43 7.6k 2.9k 1.9k 1.3k 1.1k 75 10.4k
Catherine de Martel France 26 4.9k 0.6× 3.4k 1.2× 1.1k 0.6× 1.2k 1.0× 2.1k 2.0× 41 10.7k
Mireia Díaz Spain 25 6.9k 0.9× 2.9k 1.0× 1.5k 0.8× 565 0.4× 1.4k 1.3× 43 9.2k
Heather L. Sings United States 34 4.8k 0.6× 1.5k 0.5× 1.5k 0.8× 478 0.4× 522 0.5× 59 5.8k
Gary M. Clifford France 61 14.5k 1.9× 7.9k 2.7× 541 0.3× 1.3k 1.0× 2.5k 2.3× 171 19.6k
Cladd E. Stevens United States 55 9.8k 1.3× 1.1k 0.4× 8.4k 4.5× 2.9k 2.3× 1.3k 1.2× 123 17.4k
M. Michele Manos United States 48 15.0k 2.0× 6.0k 2.1× 790 0.4× 2.1k 1.7× 3.6k 3.3× 90 18.9k
Nicola P. Klein United States 52 5.5k 0.7× 1.0k 0.3× 579 0.3× 715 0.6× 711 0.7× 295 10.0k
Lindsey R. Baden United States 56 5.0k 0.7× 720 0.2× 985 0.5× 1.2k 0.9× 1.1k 1.0× 230 10.7k
Howard D. Strickler United States 53 3.9k 0.5× 2.0k 0.7× 342 0.2× 602 0.5× 1.7k 1.6× 227 8.6k
Brian J. McMahon United States 57 16.1k 2.1× 1.3k 0.4× 14.8k 8.0× 1.5k 1.2× 793 0.7× 210 19.1k

Countries citing papers authored by Eliav Barr

Since Specialization
Citations

This map shows the geographic impact of Eliav Barr's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Eliav Barr with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Eliav Barr more than expected).

Fields of papers citing papers by Eliav Barr

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Eliav Barr. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Eliav Barr. The network helps show where Eliav Barr may publish in the future.

Co-authorship network of co-authors of Eliav Barr

This figure shows the co-authorship network connecting the top 25 collaborators of Eliav Barr. A scholar is included among the top collaborators of Eliav Barr based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Eliav Barr. Eliav Barr is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Lawitz, Eric, Fred Poordad, Leah J. Anderson, et al.. (2019). Efficacy and safety of ruzasvir 60 mg and uprifosbuvir 450 mg for 12 weeks in adults with chronic hepatitis C virus genotype 1, 2, 3, 4 or 6 infection. Journal of Viral Hepatitis. 26(6). 675–684. 5 indexed citations
3.
Serfaty, Lawrence, Ira M. Jacobson, Jürgen K. Rockstroh, et al.. (2018). The accuracy of baseline viral load for predicting the efficacy of elbasvir/grazoprevir in participants with hepatitis C virus genotype 1a infection: An integrated analysis. Journal of Viral Hepatitis. 26(3). 329–336. 9 indexed citations
4.
Zamor, Philippe J., John M. Vierling, Reem Ghalib, et al.. (2018). Elbasvir/Grazoprevir in Black Adults With Hepatitis C Virus Infection: A Pooled Analysis of Phase 2/3 clinical Trials. The American Journal of Gastroenterology. 113(6). 863–871. 2 indexed citations
5.
Jacobson, Ira M., Eric Lawitz, Paul Y. Kwo, et al.. (2017). Safety and Efficacy of Elbasvir/Grazoprevir in Patients With Hepatitis C Virus Infection and Compensated Cirrhosis: An Integrated Analysis. Gastroenterology. 152(6). 1372–1382.e2. 58 indexed citations
6.
7.
Roth, David, David R. Nelson, Annette Bruchfeld, et al.. (2015). Grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and stage 4–5 chronic kidney disease (the C-SURFER study): a combination phase 3 study. The Lancet. 386(10003). 1537–1545. 477 indexed citations breakdown →
8.
Rockstroh, Jürgen K., Mark Nelson, Christine Katlama, et al.. (2015). Efficacy and safety of grazoprevir (MK-5172) and elbasvir (MK-8742) in patients with hepatitis C virus and HIV co-infection (C-EDGE CO-INFECTION): a non-randomised, open-label trial. The Lancet HIV. 2(8). e319–e327. 218 indexed citations
9.
Forns, Xavier, Stuart C. Gordon, Eli Zuckerman, et al.. (2015). Grazoprevir and elbasvir plus ribavirin for chronic HCV genotype-1 infection after failure of combination therapy containing a direct-acting antiviral agent. Journal of Hepatology. 63(3). 564–572. 109 indexed citations
10.
Giuliano, Anna R., Joel M. Palefsky, Stephen E. Goldstone, et al.. (2011). Efficacy of Quadrivalent HPV Vaccine against HPV Infection and Disease in Males. New England Journal of Medicine. 364(5). 401–411. 821 indexed citations breakdown →
11.
Woelber, Linn, Karin Hellner, Friederike Gieseking, et al.. (2008). Baseline characteristics and prevalence of HPV 6, 11, 16, 18 in young German women participating in phase III clinical trials of a quadrivalent HPV (6/11/16/18) vaccine. Archives of Gynecology and Obstetrics. 279(6). 803–807. 4 indexed citations
12.
Barr, Eliav, Christine K. Gause, Oliver Bautista, et al.. (2008). Impact of a prophylactic quadrivalent human papillomavirus (types 6, 11, 16, 18) L1 virus-like particle vaccine in a sexually active population of North American women. American Journal of Obstetrics and Gynecology. 198(3). 261.e1–261.e11. 25 indexed citations
13.
Reisinger, Keith S., Stan L. Block, Eduardo Lazcano‐Ponce, et al.. (2007). Safety and Persistent Immunogenicity of a Quadrivalent Human Papillomavirus Types 6, 11, 16, 18 L1 Virus-Like Particle Vaccine in Preadolescents and Adolescents. The Pediatric Infectious Disease Journal. 26(3). 201–209. 225 indexed citations
14.
Mao, Constance, Laura A. Koutsky, Kevin A. Ault, et al.. (2006). Efficacy of Human Papillomavirus-16 Vaccine to Prevent Cervical Intraepithelial Neoplasia. Obstetrical & Gynecological Survey. 61(5). 315–316. 21 indexed citations
15.
Mao, Constance, Laura A. Koutsky, Kevin A. Ault, et al.. (2006). Efficacy of Human Papillomavirus-16 Vaccine to Prevent Cervical Intraepithelial Neoplasia. Obstetrics and Gynecology. 107(1). 18–27. 338 indexed citations
16.
Théroux, Pierre, Jocelyn Dupuis, Yves Pesant, et al.. (2001). Upstream use of tirofiban in patients admitted for an acute coronary syndrome in hospitals with or without facilities for invasive management. The American Journal of Cardiology. 87(4). 375–380. 19 indexed citations
17.
Brown, Darron R., Janine T. Bryan, Jill M. Schroeder, et al.. (2001). Neutralization of Human Papillomavirus Type 11 (HPV‐11) by Serum from Women Vaccinated with Yeast‐Derived HPV‐11 L1 Virus‐like Particles: Correlation with Competitive Radioimmunoassay Titer. The Journal of Infectious Diseases. 184(9). 1183–1186. 63 indexed citations
18.
Weintraub, William S, Steven D. Culler, Andrzej S. Kosinski, et al.. (1999). Economics, health-related quality of life, and cost-effectiveness methods for the TACTICS (Treat Angina with Aggrastat® [tirofiban] and Determine Cost of Therapy with Invasive or Conservative Strategy)–TIMI 18 trial. The American Journal of Cardiology. 83(3). 317–322. 27 indexed citations
19.
20.
Parmacek, Michael S., A Vora, Tingliang Shen, et al.. (1992). Identification and Characterization of a Cardiac-Specific Transcriptional Regulatory Element in the Slow/Cardiac Troponin C Gene. Molecular and Cellular Biology. 12(5). 1967–1976. 99 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Catherine de Martel Breakdown of academic impact, for papers by Mireia Díaz Breakdown of academic impact, for papers by Heather L. Sings Breakdown of academic impact, for papers by Gary M. Clifford Breakdown of academic impact, for papers by Cladd E. Stevens Breakdown of academic impact, for papers by M. Michele Manos Breakdown of academic impact, for papers by Nicola P. Klein Breakdown of academic impact, for papers by Lindsey R. Baden Breakdown of academic impact, for papers by Howard D. Strickler Breakdown of academic impact, for papers by Brian J. McMahon
Rankless by CCL
2026